Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05166616 | Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 8 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05290597 | A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas | active not recruiting | Phase 1 | 40 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 5, 2026 |
| clinicaltrials |
| NCT06883630 | A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC | active not recruiting | Phase 1 | 121 | RemeGen Co., Ltd.INDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06961786 | TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma(TUNINTIL-2) | active not recruiting | Phase 1 | 9 | TILT Biotherapeutics Ltd.INDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03070327 | BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma | active not recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2(rQNestin) | active not recruiting | Phase 1 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03223155 | Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer(COSINR) | active not recruiting | Phase 1 | 78 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03741127 | Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 | active not recruiting | Phase 1 | 100 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03844815 | Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 26 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05846867 | A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 170 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05078866 | Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients | active not recruiting | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 2 | Mar 3, 2026 | clinicaltrials |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 174 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT02721459 | XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | active not recruiting | Phase 1 | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT01684397 | Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03272334 | Her2-BATS and Pembrolizumab in Metastatic Breast Cancer(Breast-47) | active not recruiting | Phase 1 / Phase 2 | 22 | University of VirginiaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03434769 | AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma | active not recruiting | Phase 1 | 31 | Benjamin TomlinsonOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04270149 | Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer | active not recruiting | Phase 1 | 8 | Herbert LyerlyOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04294628 | Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04336241 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | active not recruiting | Phase 1 | 36 | Replimune, Inc.INDUSTRY | 2 | Feb 27, 2026 | clinicaltrials |
| NCT04943536 | Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer(BiolenRT) | active not recruiting | Phase 1 | 20 | Alessa Therapeutics Inc.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05869539 | ACT-TIL and ANV419 for Advanced Melanoma.(BaseTIL-03M) | active not recruiting | Phase 1 | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT02716116 | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 334 | TakedaINDUSTRY | 10 | Feb 25, 2026 | clinicaltrials |
| NCT03974217 | Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts | active not recruiting | Phase 1 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04764942 | Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | active not recruiting | Phase 1 / Phase 2 | 39 | Mayo ClinicOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05261750 | Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer | active not recruiting | Phase 1 / Phase 2 | 15 | PT. Prodia Stem Cell IndonesiaINDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05642962 | Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) | active not recruiting | Phase 1 / Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06052813 | A Study of BN104 in the Treatment of Acute Leukemia | active not recruiting | Phase 1 / Phase 2 | 66 | Institut de Recherches Internationales Servier (I.R.I.S.)INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT00378105 | Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 68 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04471727 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | active not recruiting | Phase 1 / Phase 2 | 232 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05176470 | Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients | active not recruiting | Phase 1 | 2 | Richard WuOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05438420 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Qurient Co., Ltd.INDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT02353819 | Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer | active not recruiting | Phase 1 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03089203 | CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer | active not recruiting | Phase 1 | 23 | University of PennsylvaniaOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03641755 | Olaparib + Sapacitabine in BRCA Mutant Breast Cancer | active not recruiting | Phase 1 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04971499 | A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma | active not recruiting | Phase 1 / Phase 2 | 26 | April Salama, M.D.OTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05527184 | First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | active not recruiting | Phase 1 | 256 | AbbVieINDUSTRY | 10 | Feb 20, 2026 | clinicaltrials |
| NCT05577000 | Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 5 | Thomas Martin, MDOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT00544466 | Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies | active not recruiting | Phase 1 / Phase 2 | 75 | City of Hope Medical CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03252938 | Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors(INSIGHT) | active not recruiting | Phase 1 | 83 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03930953 | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) | active not recruiting | Phase 1 / Phase 2 | 438 | CelgeneINDUSTRY | 15 | Feb 19, 2026 | clinicaltrials |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | active not recruiting | Phase 1 / Phase 2 | 194 | Merus B.V.INDUSTRY | 9 | Feb 19, 2026 | clinicaltrials |
| NCT02422381 | MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 16 | Providence Health & ServicesOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06483334 | A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) | active not recruiting | Phase 1 / Phase 2 | 38 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Feb 18, 2026 | clinicaltrials |
| NCT02157051 | Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer | active not recruiting | Phase 1 | 42 | University of WashingtonOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03033914 | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | active not recruiting | Phase 1 / Phase 2 | 82 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Feb 17, 2026 | clinicaltrials |
| NCT04606316 | Surgical Nivolumab And Ipilimumab For Recurrent GBM | active not recruiting | Phase 1 | 63 | Patrick Wen, MDOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05391750 | Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma | active not recruiting | Phase 1 | 7 | Emory UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05551936 | A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | active not recruiting | Phase 1 / Phase 2 | 42 | Vaishalee KenkreOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06342908 | A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma | active not recruiting | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 5, 2026source: clinicaltrials